A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Inclusion Criteria

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Has histologically or cytologically confirmed cancer that meets criteria as defined in the protocol
• Expansion Cohorts only: Is anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) naïve, defined as never having previously been treated with a drug that targets the PD-1
• Has at least 1 lesion that meets study criteria as defined in the protocol
• Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy) from a tumor site that has not been previously irradiated
• Has adequate organ and bone marrow function as defined in the protocol
• In the judgement of the investigator, has a life expectancy of at least 3 months Key

Exclusion Criteria

• Is currently participating in another study of a therapeutic agent
• Has participated in any study of an investigational agent or an investigational device within 4 weeks of the first administration of study drug as defined in the protocol
• Has received treatment with an approved systemic therapy within 4 weeks of the first administration of study drug or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities
• Has received recent anti-epidermal growth factor receptor (EGFR) antibody therapy as defined in the protocol
• Has received radiation therapy or major surgery within 14 days of the first administration of study drug or has not recovered (ie, grade 1 or baseline) from adverse events
• Has received any previous systemic, non-immunomodulatory biologic therapy within 4 weeks of first administration of study drug.
• Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as defined in the protocol
• Has second malignancy that is progressing or requires active treatment as defined in the protocol
• Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first dose of study drug as defined in the protocol
• Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or any other condition that required treatment with systemic immunosuppressive treatments as defined in the protocol
• Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression
• Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or uncontrolled seizures within 1 year prior to the first dose of study drug
• Has any ongoing inflammatory skin disease as defined in the protocol NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply